{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-040238","form_type":"8-K","ticker":"MGX","cik":"0001785279","company_name":"Metagenomi Therapeutics, Inc.","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.850577+00:00","generated_at":"2026-05-24T16:01:53.843829+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Metagenomi reports $248.3M cash; hemophilia A program on track for IND in 2026","bullets":["Cash, cash equivalents, and marketable securities $248.3M as of Dec 31, 2024; runway into 2027.","FY2024 R&D expense $109.2M (up from $94.4M); G&A expense $32.0M (up from $28.8M).","Hemophilia A program MGX-001: sustained FVIII activity in NHP >16 months; IND submission expected 2026.","Ionis collaboration: four Wave 1 targets in lead optimization; plans to nominate 1-2 DCs in 2025.","Board addition: Eric Bjerkholt (CFO of Mirum Pharmaceuticals) joins audit and compensation committees."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-040238","json":"https://secwatch.observer/filing/0000950170-25-040238.json","markdown":"https://secwatch.observer/filing/0000950170-25-040238.md","text":"https://secwatch.observer/filing/0000950170-25-040238.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785279/000095017025040238/0000950170-25-040238-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785279/000095017025040238/mgx-20250317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T16:01:53.843829+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}